A-STAR: New Systemic Therapy		
Patient Study ID:	Initials:	

New systemic therapy (for additional therapies print further CRF pages)		
Name of therapy:	□ Lebrikizumab	
□ Oral Azathioprine	□ Nemolizumab	
☐ Oral Ciclosporin	□ Rocatinlimab	
□ Oral Methotrexate	□ Subcutaneous Dupilumab	
□ Oral Mycophenolate mofetil	□ Tralokinumab	
□ Oral Prednisolone	□ Upadacitinib	
☐ Subcutaneous Methotrexate	☐ Other (specify below, including route of	
☐ Subcutaneous Omalizumab	administration):	
☐ Abrocitinib		
□ Baricitinib	□ Investigational medication (specify below & route of administration):	
Dose: mg		
Frequency: Daily Weekly Other		
Start date:		
Ongoing: Yes No		
Stop date:		
Effect:	Reason for stopping:	
☐ Excellent (Clearance)	☐ Insufficient response	
□ Good	☐ Relapse (after initial good response)	
☐ Moderate	☐ Side effect	
□ Poor	☐ Cumulative dose	
□ Unknown	□ Remission	
	☐ Other:	

A-STAR: New Systemic Therapy		
Patient Study ID:	Initials:	

New systemic therapy (for additional therapies print further CRF pages)		
Name of therapy:	□ Lebrikizumab	
□ Oral Azathioprine	□ Nemolizumab	
☐ Oral Ciclosporin	□ Rocatinlimab	
□ Oral Methotrexate	□ Subcutaneous Dupilumab	
□ Oral Mycophenolate mofetil	□ Tralokinumab	
□ Oral Prednisolone	□ Upadacitinib	
☐ Subcutaneous Methotrexate	☐ Other (specify below, including route of	
☐ Subcutaneous Omalizumab	administration):	
☐ Abrocitinib		
□ Baricitinib	□ Investigational medication (specify below & route of administration):	
Dose: mg		
Frequency: Daily Weekly Other		
Start date:		
Ongoing: Yes No		
Stop date:		
Effect:	Reason for stopping:	
☐ Excellent (Clearance)	☐ Insufficient response	
□ Good	☐ Relapse (after initial good response)	
☐ Moderate	☐ Side effect	
□ Poor	☐ Cumulative dose	
□ Unknown	□ Remission	
	☐ Other:	